AI assistant
AGRONOMICS LIMITED — Net Asset Value 2013
Jul 11, 2013
7474_rns_2013-07-11_1feef045-1695-4e12-9544-42d47de7d1b4.html
Net Asset Value
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0563J
Port Erin Biopharma Investments Ltd
11 July 2013
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 June 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2013 was 10.63 pence per share, including un-invested cash of £707,624. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a decrease of 5.3% from the previous valuation of 11.22 pence per share, which included un-invested cash of £287,310. However, the combined value of investments and cash at £3.625 million represents a fall of only 2.6% on the same value last period. The revenue reserve at £0.84 million still represents a return of over 33.3% on investments after listing and operating costs."
| Unaudited to 30 June 2013 £ |
||
| Fixed Assets | ||
| Investments | 2,916,930 | |
| Current Assets | ||
| Debtors: amounts owing | 7,797 | |
| Un-invested cash | 707,624 | |
| Current Liabilities | ||
| Creditors: amounts due | (32,400) | |
| 3,599,951 | ||
| Capital and Reserves | ||
| Share Capital | 34 | |
| Share Premium | 2,759,551 | |
| Current year's earnings | 415,158 | |
| Retained earnings | 425,208 | |
| 3,599,951 | ||
| Shares in Issue | 33,864,836 | |
| Net Asset Value per share | 10.63 pence |
--- ENDS ---
Portfolio Details
| Investments Schedule at 30 June 2013 | £ Valuation | Portfolio % |
| Synergy Pharmaceuticals Inc. | 277,748 | 9.52% |
| Summit Corporation plc | 212,500 | 7.29% |
| Arrowhead Research | 207,364 | 7.11% |
| Plethora Solutions Holdings plc | 166,625 | 5.71% |
| TrovaGene Inc. | 137,224 | 4.70% |
| Pfizer Inc. | 136,562 | 4.68% |
| Nektar Therapeutics | 127,303 | 4.36% |
| Sanofi-ADR | 91,349 | 3.13% |
| 1,356,675 | 46.51% | |
| Aggregate value of remaining holdings below 3% of total portfolio | 1,560,255 | 53.49% |
| TOTAL INVESTMENTS | 2,916,930 | 100.00% |
For further information, please contact:
| Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
| The Company | Nomad | Broker |
| Denham Eke +44 162 463 9396 |
Sandy Jamieson +44 203 697 9495 |
Jon Levinson +44 207 469 0935 |
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVDMGMNKGLGFZM